OBJECTIVES: In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism (glucose transporter-1 [Glut-1]) and genes involved in angiogenesis (i.e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH). PATIENTS AND METHODS: 78 formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 36 patients with mCRC. Tumor gene expression was correlated with serum LDH levels from the same group of patients. FFPE tissues were dissected using laser-captured microdissection and analyzed for gene expression using a quantitative real-time RT-PCR method. RESULTS: Intratumoral gene expression of VEGFA and VEGFR1 showed a statistically significant correlation with serum LDH levels (p = 0.006, r = 0.45 and p = 0.004, r = 0.50, respectively). Intratumoral expression of LDHA gene showed a significant correlation with Glut-1, VEGF, HIF1 alpha, HIF2 alpha and VEGFR1 (p = 0.007, r = 0.44; p < 0.001, r = 0.57; p = 0.013, r = 0.41; p = 0.044, r = 0.34; p = 0.026, r = 0.40). Serum LDH levels also correlated with microvessel density analyzed by immunohistochemical analysis. CONCLUSION: The results demonstrated a significant correlation between the intratumoral gene expression of LDHA, HIF1 alpha, HIF2 alpha, Glut-1, NRP1, VEGFA and VEGFR1. Patients with high serum LDH have increased intratumoral gene expression of VEGFA and VEGFR1. The results also support the hypothesis that serum LDH levels may serve as a surrogate marker for activation of the HIF-related genes in the tumor.
OBJECTIVES: In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism (glucose transporter-1 [Glut-1]) and genes involved in angiogenesis (i.e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH). PATIENTS AND METHODS: 78 formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 36 patients with mCRC. Tumor gene expression was correlated with serum LDH levels from the same group of patients. FFPE tissues were dissected using laser-captured microdissection and analyzed for gene expression using a quantitative real-time RT-PCR method. RESULTS: Intratumoral gene expression of VEGFA and VEGFR1 showed a statistically significant correlation with serum LDH levels (p = 0.006, r = 0.45 and p = 0.004, r = 0.50, respectively). Intratumoral expression of LDHA gene showed a significant correlation with Glut-1, VEGF, HIF1 alpha, HIF2 alpha and VEGFR1 (p = 0.007, r = 0.44; p < 0.001, r = 0.57; p = 0.013, r = 0.41; p = 0.044, r = 0.34; p = 0.026, r = 0.40). Serum LDH levels also correlated with microvessel density analyzed by immunohistochemical analysis. CONCLUSION: The results demonstrated a significant correlation between the intratumoral gene expression of LDHA, HIF1 alpha, HIF2 alpha, Glut-1, NRP1, VEGFA and VEGFR1. Patients with high serum LDH have increased intratumoral gene expression of VEGFA and VEGFR1. The results also support the hypothesis that serum LDH levels may serve as a surrogate marker for activation of the HIF-related genes in the tumor.
Authors: Richard W Joseph; Ryan J Sullivan; Robyn Harrell; Katherine Stemke-Hale; David Panka; George Manoukian; Andrew Percy; Roland L Bassett; Chaan S Ng; Laszlo Radvanyi; Patrick Hwu; Michael B Atkins; Michael A Davies Journal: J Immunother Date: 2012-01 Impact factor: 4.456
Authors: John C Schell; Kristofor A Olson; Lei Jiang; Amy J Hawkins; Jonathan G Van Vranken; Jianxin Xie; Robert A Egnatchik; Espen G Earl; Ralph J DeBerardinis; Jared Rutter Journal: Mol Cell Date: 2014-10-21 Impact factor: 17.970
Authors: G Larry Maxwell; Brian L Hood; Roger Day; Uma Chandran; David Kirchner; V S Kumar Kolli; Nicolas W Bateman; Jay Allard; Caela Miller; Mai Sun; Melanie S Flint; Chris Zahn; Julie Oliver; Subhadra Banerjee; Tracy Litzi; Anil Parwani; Glenn Sandburg; Scott Rose; Michael J Becich; Andrew Berchuck; Elise Kohn; John I Risinger; Thomas P Conrads Journal: Gynecol Oncol Date: 2011-04-01 Impact factor: 5.482
Authors: Xabier Garcia-Albeniz; Carles Pericay; Virginia Alonso-Espinaco; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Pere Gascón; Sergi Castellví-Bel; Joan Maurel Journal: Tumour Biol Date: 2010-11-23
Authors: James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544
Authors: Michael I Koukourakis; Alexandra Giatromanolaki; Efthimios Sivridis; Kevin C Gatter; Tanja Trarbach; Gunnar Folprecht; Michael M Shi; David Lebwohl; Tarja Jalava; Dirk Laurent; Gerold Meinhardt; Adrian L Harris Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: M Scartozzi; R Giampieri; E Maccaroni; M Del Prete; L Faloppi; M Bianconi; E Galizia; C Loretelli; L Belvederesi; A Bittoni; S Cascinu Journal: Br J Cancer Date: 2012-02-07 Impact factor: 7.640